Rising Prevalence Of Gastrointestinal Disorders To Drive Market Share Growth Driver: A Major Catalyst in the Evolution of the Viral Gastroenteritis Market Share in 2025

What market dynamics are playing a key role in accelerating the growth of the viral gastroenteritis market?
The escalating incidence of disorders related to the gastrointestinal system is anticipated to drive the expansion of the viral gastroenteritis market in the future. The term gastrointestinal (GI) disorders pertains to diseases that happen within or on any section of the gastrointestinal tract. Treatments and drugs for viral gastroenteritis offer necessary and suitable medication to those ailing from this disease. For instance, the Impact of IBD Report 2023, which was published in September 2023 by the IBD Clinical and Research Centre-a Canadian organization whose aim is to enhance the quality of life of patients suffering from Crohn's disease and ulcerative colitis-indicated that in 2023, there was an incidence of 825 per 100,000, meaning that over 320,000 Canadians had inflammatory bowel disease (IBD). Given that the incidence is projected to rise by 2.44% per year, it estimated that by 2035, 1.1% of the population or 470,000 Canadians would be living with IBD. Consequently, the growth of the viral gastroenteritis market is bolstered by the rising incidence of gastrointestinal disorders.

Get Your Viral Gastroenteritis Market Report Here:
https://www.thebusinessresearchcompany.com/report/viral-gastroenteritis-global-market-report

How will the growth rate of the viral gastroenteritis market shape industry trends by 2034?
In recent times, there has been a consistent growth in the market size of viral gastroenteritis. It is projected to rise from $6.75 billion in 2024 to $7.08 billion in 2025, recording a compound annual growth rate (CAGR) of 5.0%. The uptick experienced in the historic period is a result of the proliferation of viral infections, worldwide hygiene habits, improvements in detection methods, international travel and tourism, as well as climatic and environmental variables.

In the coming years, the market size for viral gastroenteritis is anticipated to experience robust growth. It is projected to reach $8.73 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. Factors that contribute to this expansion during the projected period include preparedness for global health issues, the effects of climate change, comprehensive health methods, systems for epidemiological surveillance, education, and public consciousness. Some of the significant trends in the forecast period encompass development of vaccines, advanced diagnostic methods, use of telemedicine for diagnosis, joint research efforts, personalized medicine strategies, and digital health resolutions.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12127&type=smp

What trends are poised to drive the future success of the viral gastroenteritis market?
The increasing importance of product innovation is a prominent trend emerging in the viral gastroenteritis market. To solidify their dominance in the market, major corporations in the industry are concentrating on the creation of new products. For instance, in November 2022, GlaxoSmithKline PLC, a biopharmaceutical enterprise based in the UK, was granted approval by the US Food and Drug Administration (FDA) for its new liquid formulation of ROTARIX, to help avoid rotavirus gastroenteritis in infants. This innovative presentation method is more user-friendly for medical professionals as it removes the requirement for vaccine dose reconstitution at the time of usage. The approval is boosted by international clinical trial findings that establish the safety and tolerability of this new formulation in comparison to the lyophilized formulation and its equivalence in immunogenicity.

Which primary segments of the viral gastroenteritis market are driving growth and industry transformations?
The viral gastroenteritis market covered in this report is segmented -

1) By Drugs: Antibiotics, Antacids, Laxatives, Antimotility Agents, Others Drugs
2) By Diagnosis: Physical Examination, Rapid Stool Test
3) By Indication: Watery Diarrhea, Abdominal Cramps, Pain, Other Indications
4) By Type Of Virus: Norovirus, Rotavirus, Astrovirus, Enteric Adenovirus
5) By End User: Hospitals, Clinics, Pharmaceutical Companies, Diagnostic Centers, Ambulatory Care Centers, Others End Users

Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Penicillins, Macrolides, Cephalosporins
2) By Antacids: Proton Pump Inhibitors (PPIs), Histamine-2 Receptor Antagonists (H2 Blockers), Magnesium-Based Antacids, Calcium-Based Antacids, Sodium Bicarbonate
3) By Laxatives: Bulk-Forming Laxatives, Osmotic Laxatives, Stimulant Laxatives, Stool Softeners
4) By Antimotility Agents: Loperamide, Diphenoxylate
5) By Other Drugs: Oral Rehydration Salts (Ors), Zinc Supplements, Antiemetics

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12127

Which geographical regions are pioneering growth in the viral gastroenteritis market?
North America was the largest region in the viral gastroenteritis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the viral gastroenteritis market landscape?
Major companies operating in the viral gastroenteritis market include Pfizer Inc., Abbvie Inc., Sanofi S.A., Abbott Laboratories, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, C.H. Boehringer Sohn AG & Co. KG, Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics Plc, Dr. Reddy's Laboratories Ltd., BioMarin Pharmaceutical Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd, Ironwood Pharmaceuticals Inc, ANI Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Allergan plc, Haustus Biotech Private Limited, Gracia Lifesciences India Private Limited

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12127&type=smp

What Is Covered In The Viral Gastroenteritis Global Market Report?

• Market Size Forecast: Examine the viral gastroenteritis market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the viral gastroenteritis market for a structured understanding.
• Key Players Overview: Analyze major players in the viral gastroenteritis market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the viral gastroenteritis market.
• Segment Contributions: Evaluate how different segments drive overall growth in the viral gastroenteritis market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the viral gastroenteritis market.
• Industry Challenges: Identify potential risks and obstacles affecting the viral gastroenteritis market.
• Competitive Landscape: Review strategic developments in the viral gastroenteritis market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.